Binge Eating Disorder Treatment Market
Binge Eating Disorder Treatment Market Scope:
Request Sample Report
Binge Eating Disorder Treatment Market Size and Growth
The Binge Eating Disorder Treatment market is expanding significantly, driven by increasing awareness and improved therapeutic options. Current market size estimates exceed $3 billion, with a projected CAGR of over 12% in the coming years. Rising prevalence of binge eating disorders and telehealth adoption are key factors shaping market dynamics.
Companies Covered
(Covid 19 Impact Covered)
◍ Chronos Therapeutics
◍ Shire US Inc. (part of Takeda Pharmaceutical Company)
◍ Eli Lilly and Company
◍ Sunovion Pharmaceuticals Inc
◍ Promises Behavioral Health
◍ Pyramid Healthcare (Tapestry Eating Disorder Services)
◍ Timberline Knolls
The Binge Eating Disorder Treatment Market features companies like Chronos Therapeutics, Shire (Takeda), Eli Lilly, and Sunovion, which develop medications and therapies. Facilities like Promises Behavioral Health and Timberline Knolls provide specialized care, while Roche and Opiant are innovating treatments, driving market growth through diverse approaches and expanding access to care.
- Eli Lilly: $28 billion (2022 revenue)
- Takeda Pharmaceutical: $20 billion (2022 revenue)
- Novo Nordisk: $24 billion (2022 revenue)
◍ Rosewood Centers for Eating Disorders
◍ Walden Behavioral Care
◍ Roche
◍ Opiant Pharmaceuticals
◍ Heptares
◍ Novo Nordisk
◍ Omeros Corp
Request Sample Report
Market Segmentation
By Application
Hospitals
Clinics
Request Sample Report
By Product
Medication
Services
$ 1440.00 Billion
Request Sample Report
